Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $21.54 in the last session, down -1.33% from day before closing price of $21.83. In other words, the price has decreased by -$1.33 from its previous closing price. On the day, 0.69 million shares were traded. TARS stock price reached its highest trading level at $22.17 during the session, while it also had its lowest trading level at $20.0818.
Ratios:
We take a closer look at TARS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.92 and its Current Ratio is at 8.01. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Neutral rating and assigned the stock a target price of $19.
On July 18, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $44.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 18 ’24 when Farrow Jeffrey S sold 10,445 shares for $27.47 per share. The transaction valued at 286,924 led to the insider holds 18,136 shares of the business.
Azamian Bobak R. sold 10,415 shares of TARS for $318,699 on Mar 18 ’24. The President/CEO and Board Chair now owns 26,456 shares after completing the transaction at $30.60 per share. On Mar 18 ’24, another insider, Neervannan Seshadri, who serves as the Chief Operating Officer of the company, sold 4,879 shares for $30.60 each. As a result, the insider received 149,297 and left with 64,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 813817856 and an Enterprise Value of 547417664. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.12 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 12.862 whereas that against EBITDA is -3.535.
Stock Price History:
Over the past 52 weeks, TARS has reached a high of $42.50, while it has fallen to a 52-week low of $12.57. The 50-Day Moving Average of the stock is -26.08%, while the 200-Day Moving Average is calculated to be -20.71%.
Shares Statistics:
According to the various share statistics, TARS traded on average about 687.94K shares per day over the past 3-months and 798210 shares per day over the past 10 days. A total of 34.21M shares are outstanding, with a floating share count of 31.03M. Insiders hold about 17.86% of the company’s shares, while institutions hold 98.73% stake in the company. Shares short for TARS as of 1721001600 were 8805240 with a Short Ratio of 12.80, compared to 1718323200 on 7963194. Therefore, it implies a Short% of Shares Outstanding of 8805240 and a Short% of Float of 24.159999.
